Neurovascular disorders, such as strokes and aneurysms, present significant global health and economic challenges. Robotic systems in neurovascular interventions offer promising improvements in procedural precision, safety, and clinical outcomes; however, their high acquisition and operational costs require rigorous financial justification. This study developed a service line-focused cost-benefit model to evaluate the financial viability and strategic value of robotic-assisted neurovascular systems. Using a mixed-methods approach, the study integrated a five-year deterministic financial model with qualitative interviews involving clinicians, hospital administrators, and strategic planners. Data were derived from vendor pricing, peer-reviewed literature, hospital budget reports, and expert insights. The model incorporated capital, operational, and clinical parameters and included sensitivity analyses to assess key variables such as procedural volume, reimbursement rates, and complication-related savings. Results indicated a projected net benefit of $21.4 million over five years under baseline assumptions, with procedural volume being the most influential factor in financial outcomes. Break-even analysis revealed that a minimum of 150 procedures per year is required for viability. Qualitative findings emphasized non-financial advantages, including improved physician recruitment, institutional prestige, and tele-robotic capabilities. These findings offer hospital decision-makers a comprehensive framework for evaluating robotic investments in neurovascular care.

neurovascular care, robotics, cost-benefit analysis, service line, hospital investment, procedural volume